These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 11934073)

  • 1. Optimization study of doxorubicin liposomal preparations coated with laminin fragments.
    Almiñana N; Polo D; Alsina MA; Reig F
    Prep Biochem Biotechnol; 2002 Feb; 32(1):1-16. PubMed ID: 11934073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biodistribution study of doxorubicin encapsulated in liposomes: influence of peptide coating and lipid composition.
    Almiñana N; Polo D; Rodríguez L; Reig F
    Prep Biochem Biotechnol; 2004 Feb; 34(1):77-96. PubMed ID: 15046298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
    Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH
    Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation.
    Bhatia A; Kumar R; Katare OP
    J Pharm Pharm Sci; 2004 Jul; 7(2):252-9. PubMed ID: 15367383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.
    Mayer LD; Tai LC; Ko DS; Masin D; Ginsberg RS; Cullis PR; Bally MB
    Cancer Res; 1989 Nov; 49(21):5922-30. PubMed ID: 2790807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol).
    Parr MJ; Masin D; Cullis PR; Bally MB
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1319-27. PubMed ID: 9067319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interfacial interactions of hydrophobic peptides with lipid bilayers.
    Reig F; Haro I; Polo D; Egea MA; Alsina MA
    J Colloid Interface Sci; 2002 Feb; 246(1):60-9. PubMed ID: 16290384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and characterization of doxorubicin liposomes.
    Niu G; Cogburn B; Hughes J
    Methods Mol Biol; 2010; 624():211-9. PubMed ID: 20217598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentapeptide YIGSR-mediated HT-1080 fibrosarcoma cells targeting of adriamycin encapsulated in sterically stabilized liposomes.
    Lopez-Barcons LA; Polo D; Reig F; Fabra A
    J Biomed Mater Res A; 2004 Apr; 69(1):155-63. PubMed ID: 14999763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
    J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular targeting of doxorubicin using cationic liposomes.
    Wu J; Lee A; Lu Y; Lee RJ
    Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation kit for liposomal doxorubicin composed of lyophilized liposomes.
    Stevens PJ; Lee RJ
    Anticancer Res; 2003; 23(1A):439-42. PubMed ID: 12680245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated liposomal doxorubicin in ovarian cancer.
    Green AE; Rose PG
    Int J Nanomedicine; 2006; 1(3):229-39. PubMed ID: 17717964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses.
    Guan HH; Budzynski W; Koganty RR; Krantz MJ; Reddish MA; Rogers JA; Longenecker BM; Samuel J
    Bioconjug Chem; 1998; 9(4):451-8. PubMed ID: 9667946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The liposomal formulation of doxorubicin.
    Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
    Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel O-palmitoylscleroglucan-coated liposomes as drug carriers: development, characterization and interaction with leuprolide.
    Carafa M; Marianecci C; Annibaldi V; Di Stefano A; Sozio P; Santucci E
    Int J Pharm; 2006 Nov; 325(1-2):155-62. PubMed ID: 16884870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphoid tissue targeting of anti-HIV drugs using liposomes.
    Désormeaux A; Bergeron MG
    Methods Enzymol; 2005; 391():330-51. PubMed ID: 15721390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenic vessel-targeting DDS by liposomalized oligopeptides.
    Asai T; Oku N
    Methods Mol Biol; 2010; 605():335-47. PubMed ID: 20072892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model.
    Cabanes A; Tzemach D; Goren D; Horowitz AT; Gabizon A
    Clin Cancer Res; 1998 Feb; 4(2):499-505. PubMed ID: 9516942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
    Hong RL; Tseng YL
    Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.